Entropy Technologies LP Buys Shares of 2,332 HealthEquity, Inc. (NASDAQ:HQY)

Entropy Technologies LP acquired a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,332 shares of the company's stock, valued at approximately $224,000.

A number of other hedge funds also recently bought and sold shares of HQY. Wasatch Advisors LP raised its stake in shares of HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company's stock worth $635,065,000 after acquiring an additional 483,269 shares in the last quarter. State Street Corp raised its position in HealthEquity by 0.8% in the 3rd quarter. State Street Corp now owns 3,131,900 shares of the company's stock worth $256,346,000 after purchasing an additional 23,613 shares during the period. Geode Capital Management LLC lifted its stake in HealthEquity by 0.7% in the third quarter. Geode Capital Management LLC now owns 2,078,977 shares of the company's stock worth $170,197,000 after purchasing an additional 15,145 shares during the last quarter. Franklin Resources Inc. boosted its position in HealthEquity by 0.7% during the third quarter. Franklin Resources Inc. now owns 1,640,215 shares of the company's stock valued at $139,369,000 after buying an additional 11,659 shares during the period. Finally, Loomis Sayles & Co. L P grew its stake in shares of HealthEquity by 2.2% during the third quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company's stock valued at $92,216,000 after buying an additional 24,665 shares during the last quarter. Institutional investors own 99.55% of the company's stock.

Insider Activity

In related news, Director Stuart B. Parker sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the completion of the transaction, the director now owns 19,061 shares of the company's stock, valued at $1,843,579.92. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the business's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $101.56, for a total value of $837,870.00. Following the completion of the sale, the director now directly owns 66,469 shares in the company, valued at $6,750,591.64. This trade represents a 11.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,000 shares of company stock worth $3,895,788. Corporate insiders own 2.20% of the company's stock.

HealthEquity Stock Down 1.1 %

HQY traded down $1.25 on Monday, hitting $112.69. The company had a trading volume of 483,217 shares, compared to its average volume of 763,365. HealthEquity, Inc. has a 52-week low of $65.01 and a 52-week high of $115.59. The stock has a fifty day simple moving average of $102.38 and a 200-day simple moving average of $91.18. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a market capitalization of $9.77 billion, a P/E ratio of 103.39, a P/E/G ratio of 1.61 and a beta of 0.55.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its earnings results on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the previous year, the firm posted $0.40 earnings per share. As a group, equities analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. BTIG Research increased their target price on HealthEquity from $110.00 to $130.00 and gave the company a "buy" rating in a report on Thursday, November 14th. JMP Securities increased their price objective on HealthEquity from $105.00 to $107.00 and gave the company a "market outperform" rating in a research note on Tuesday, December 10th. Mizuho began coverage on shares of HealthEquity in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 target price on the stock. The Goldman Sachs Group began coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a "neutral" rating and a $108.00 price target for the company. Finally, Royal Bank of Canada boosted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, HealthEquity has a consensus rating of "Moderate Buy" and a consensus target price of $110.71.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.